skip to contentNational Cancer Institute
National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Clinical Genetics Branch

Publications

All CGB Publications

Selected Publications

  • Katki HA, Gail MH, Greene MH. Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families. Lancet Oncol 2007; 8: 1042-1043
  • Antoniou AC, Spurdle AB, Sinilnikova OM, Greeme MH, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82:937-948 [PMCID: 2427217]
  • Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PloS One 2009; 4:e4812 [PMCID: 2652075]
  • Mai PL, Wideroff L, Greene MH, Graubard BI. Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study. Public Health Genomics 2010; 13:495-503 [PMCID: 3025897]
  • Korde LA, Mueller CM, Loud LT, Struewing JP, Nichols K, Greene MH, Mai PL. No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. Breast Cancer Res Treat 2011; 125:169-173 [PMCID: 3110729]
  • Mai PL, Gail MH, Greene MH, Willis GB, Wideroff L. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 2011; 103:788-797 [PMCID: 3096799]
  • Chang S, Wang RH, Akagi K, Mai PL, Greene MH, et al.: Tumor suppressor BRCA1 epigenetically controls oncogenic miRNA-155. Nature Medicine 2011; September 25, Epub ahead of print
  • Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard B, Loud JT, Greene MH. Unpacking the blockers: Understanding perceptions and social constraints of health communication in Hereditary Breast Ovarian Cancer (HBOC) susceptibility families. J Genet Couns 2011; 20(5); :450-464
  • Korde LA, Premkumar A, Mueller C, Rosenberg P, Soho C, Bratslavsky G, Greene MH. Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives. Br J Cancer 2008; 99: 1748-1753 [PMCID: 2584936]
  • Horvath A, Korde L, Greene MH, et al. Functional phosphodiesterase 11a mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res 2009; 69:5301-5306 [PMCID: 2734464]
  • Mirabello L, Savage SA, Lorde L, Gadalla SM, Greene MH. LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet 2010; 11:77 [PMCID: 2880977]
  • Kratz CP, Mai PL, Greene MH. Familial testicular germ cell tumours. Best Pract Res Clin Endocrinol Metab 2010; 24:503-513 [PMCID: 2939736]
  • Kratz CP, Bratslavsky G, Shi J. The clinical utility of testicular cancer risk loci. Genome Med 2011; 3:1 [PMCID: 3092086]
  • Kratz CP, Han SS, Rosenberg PS, Berndt SI, Burdett L, Yeager M, Korde LA, Mai PL, Pfeiffer R, Greene MH. Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Med Genet 2011; 48:473-476 [PMCID: 3131696]
  • Kratz CP, Greene MH, Bratslavsky G, Shi J. A stratified genetic risk assessment for testicular cancer. Int J Androl 2011; 34:e98-e102 [PMCID: 3145032]
  • Mai PL, Friedlander M, Tucker K, Greene MH. The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol 2010; 28:492-499 [PMCID: 2891341]
  • Alter, BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007; 44:1-9 [PMCID: 2597906]
  • Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007; 92:2624-2631
  • Hutson SP, Alter BP. Experiences of siblings of patients with Fanconi anemia. Pediatr Blood Cancer 2007; 48:72-70
  • Denny CC, Wilfond BS, Peters JA, Giri N, Alter BP. All in the family: Disclosure of "unwanted" information to an adolescent to benefit a relative. Am J Med Genet A 2008; 146A:2719-2724 [PMCID: 3143002]
  • Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 2008; 140:210-213 [PMCID: 3143022]
  • Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L, Carr AG, Greene MH, Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150:170-188 [PMCID: 3125983]
  • Rosenberg PS, Zeidler C, Bolyard AA, Alter BP, Bonilla MA, Boxer LA, Dror Y, Kinsey S, Link DC, Newburger PE, Shimamura A, Welte K, Dale DC. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010; 150:196-199 [PMCID: 2906693]
  • Biswas K, Das R, Alter BP, et al. A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse as cell-based assay. Blood 2011; 118(9):2430-42
  • Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007; 110:1439-1447 [PMCID: 1975834]
  • Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008; 82:501-509 [PMCID: 2427222]
  • Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL, Giri N, Greene MH, Orchard PJ, Tolar J, Tsilou E, Van Waes C, Wong JM, Young NS, Alter BP. Dyskeratosis congenita: The first NIH clinical research workshop. Pediatr Blood Cancer 2009; 53:520-523 [PMCID: 2739803]
  • Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood 2009; 113:6549-6557 [PMCID: 2710915]
  • Batista LF, Pech MF, Zhong FL, Savage SA, Reijo Pera RA, Artandi SE. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011; 474:300-402
  • Giri N, Lee R, Faro A, Huddleston CB, White FV, Alter BP, Savage SA. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case report and systematic literature review. BMC Blood Disord 2011; 11:3 [PMCID: 3141321]
  • Savage SA, Giri N, Jessop L, Pike K, Plona T, Burdett L, Alter BP. Sequence analysis of the shelterin telomere protection complex genes in dyskeratosis congenita. J Med Genet 2011; 48:285-288
  • Zhong F, Savage SA, Shkreli M, Giri N, Jessop L, Myers T, Chen R, Alter BP, Artandi SE. Disruption of telomerase trafficking by TCBA1 mutation causes dyskeratosis congenita. Genes Dev 2011; 25:11-16 [PMCID: 3012932]
  • Canudas S, Houghtaling B, Bhanot M, Sasa G, Savage SA, Bertuch AA, Smith S. A role for heterochromatin protein 1 gamma at human telomeres. Genes Dev 2011; 25(17): 1807-19
  • Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT, 3rd, Greene MH. Hypotheis: Neoplasms in myotonic dystrophy. Cancer Causes Control 2009; 20:2009-2020 [PMCID: 3110730]
  • Denayer E, Descheemaeker M-J, Stewart DR, Keymolen K, Coombes SL, Snow J, Thurm AE, Joseph LA, Fryns J-P, Legius E. Observations on intelligence and behavior in 15 patients with Legius syndrome. Am J Med Genet C Semin Med Genet 2011; 157: 123-128 [PMCID: 3081633]
  • Chao MM, Todd MA, Kontny U, Neas K, Sullivan MJ, Hunter AG, Picketts DJ, Kratz CP. T-cell acute lymphoblastic leukemia in association with Börjeson-Forssman-Lehmann syndrome due to a mutation in PHF6. Pediatr Blood Cancer 2010; 55:722-724 [PMCID: 2933084]
  • Cirtea IC, Kutsche K, Dvorsky R, Kratz CP, et al . A restricted spectrum of NRAS mutation causes Noonan syndrome. Nat Genet 2010; 42:27-29 [PMCID: 3118669]
  • Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica 2010; 95:699-701 [PMCID: 2864372]
  • Gremer L, Merbitz-Zahradnik T, Kratz CP, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 2011; 32:33-43 [PMCID: 3117284]
  • Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, Cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011; 157:83-89 [PMCID: 3086183]
  • Hoskins LM, Roy K, Peters JA, Loud JT, Greene MH. Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support. Fam Syst health 2008; 26:296-316
  • Koehly LM, Peter JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, Loud JT, Greene MH. Characteristics of health information gatherers, dissemiantors, and blockers within families at risk of hereditary cancer: Implications for family health communication interventions. Am J Public Health 2009; 99:2203-2209 [PMCID: 2775786]
  • Loud JT, Beckjord EB, Nichols K, Peters J, Giusti R, Greene MH. Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Womens Health 2009; 9:20 [PMCID: 2731043]
  • Greene MH, Piedmont M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud JT, Rodrigues G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S. A prospective study of risk-reducing salpino-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Dsign and baseline characteristics: A Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 2008; 17:594-604 [PMCID: 3125978]
  • Greene MH, Mai PL. What have we learned from risk-reducing salpingo-oophorectomy? J Natl Cancer Inst2009; 101:70-71 [PMCID: 2639316]
  • Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinsin G, Olopade OI, Couch FJ, Wang Z, Lindor NM, Pankratz VS, Radice P, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernstrom H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Duran M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N,van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Peterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Loustalot C, Nogichi T, Sobol H, Rouleau E, Nogues C, Frenay M, Venat-Bouvet L, Hopper JL, Daly MB, Terry MB, John EM, Nuys SS, Yassin Y, Miron A, Goldgar D, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jonson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schonbuchner I, Caldes T, de la Hoya M, Aittomaki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X, Platte R, Chenevix-Trench G, Easton DF. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction. Cancer Res 2010; 70:9742-9754 [PMCID: 2999830]
  • Antoniou AC, Wang X, Fredericksen ZS, Greene MH, Mai PL, Loud JT, et al . A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42:885-892 [PMCID: 3130795]
  • Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 2011; 204:19 e11-16.
  • Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) 2011; 4:303-306 [PMCID: 3077065]
  • Ramus SJ, Kartsonaki C, Gayther SAm Greene MH, Mai PL, et al . Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2011; 103: 105-116 [PMCID: 3107565]
  • Skates SL, Mai PL, Greene MH, Lu K. Large prospective study of ovarian cancer screening in high-risk women: CA 125 Cut-point defined by menopausal status. Cancer Prev Res 2011; 4(9): 1401-8
  • Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009; 115:1531-1543 [PMCID: 2813207]
  • Mirabello L, Berndt SI, Seratti GF, Burdett L, Yeager M, Chowdhury S, Teshome K, Uzoka A, Douglass C, Hayes RB, Hoover RN, Savage SA. Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. Carginogenesis 2010; 31:1400-1404 [PMCID: 2915635]
  • Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patino-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schulz J, Craft AW, Savage SA. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 2011; 22:899-908
  • Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, Teshome K, Uzoka A, Hutchinson A, Grotmol T, Douglass C, Hayes RB, Hoover RN, Savage SA. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 2011; 11:209 [PMCID: 3138419]
  • Hou L, Savage SA, Blaser MJ, Perez-Perez G, Hozha M, Dioni L, Pegoraro V, Dong LM, Zatonski W, Lissowska J, Chow WH, Baccarelli A. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:3103-3109 [PMCID: 2938741]
  • Landi MT, Chatterjee N, Yu K, Goldin L, Mirabello L, Savage SA, et al . A genome-wide association study of lung cancer identifies a region of chromosome 5pl15 associated with risk for adenocarcinoma. Am J Hum Genet 2009; 85:679-691 [PMCID: 2775843]
  • Mirabello L, Huang WY, Wong JY, Chatterjee N, Reding D, Crawford ED, De Vivo I, Hayes RB, Savage SA. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009; 8:405-413 [PMCID: 2742954]
  • Mirabello L, Garcia-Closas M, Cawthon R, Lissowska J, Brinton LA, Peplonska B, Sherman ME, Savage SA. Leukocyte telomere length in a population-based case-control study of ovarian cancer: A pilot study. Cancer Causes Control 2010; 21:77-82 [PMCID: 3130499]
  • Mirabello L, Yu K, Kraft P ,De Vivo I, Hunter DJ, Prescott J, Wong JY, Chatterjee N, Hayes RB, Savage SA. The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 2010; 31:1050-1058 {[PMCID: 2932868]
  • Prescott J, Kraft P, Chasman DI, Savage SA, Mirabello L, Berndt SI, Weissfeld JL, Han J, Hayes RB, Chanock SJ, Hunter DJ, De Vivo I. Genome-wide association study of relative relomere length. PloS One 2011; 6:e19635 [PMCID: 3091863]
  • Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2011; 20:1238-1250 [PMCID: 3118771]
  • Mirabello L, Yeager M, Chowdhury S, Qi L, Deng X, Wang Z, Hutchinson A, Savage SA. Worldwide genetic structure in 37 genes important in telomere biology. Heredity 2011; Jul 6 [Epub ahead of print]
  • Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102:315-324 [PMCID: 2831050]
  • Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M, Rodriguez AC, Sherman ME, Bratti C, Schiffman M, Wacholder S, Burk RD, Herrero R, Chanock SJ, Hildesheim A. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PloS One 2010; 5e8667 [PMCID: 2801608]
  • campos G, Rodriguez AC, Castle PC, Herrero R, Hildesheim A, Katki H, Kim JJ, Walcholder S, Morales J, Burk RD, Schiffman M. Persistence of concurrent infections with multiple human papillomavirus types: A population-based cohort study. J Infect Dis 2011; 203:823-827 [PMCID: 3071138]
  • Castle P, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, Morales J, Rydzak G, Schiffman M, for the Proyecto Guanacaste Epidemiologico (PEG) Group. Long term human persistence of prevalently detected human papillomavirus infections the absence of detectable cervical precancer and cancer. J Infect Dis 2011; 203:814-822 [PMCID: 3071125]
  • Schiffman M, Glass AG, Wentzensen N, Ruch BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD. A prospective study of type-specific human papillomavirus infection and cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20:1398-1409
  • Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Schiffman M, Demuth F, Kinney W. Variable risk of cervical precancer and cancer following a human papillomavirus-positive test. Obstet Gynecol 2011; 117:650-656
  • Castle PE, Shaber R, Lamere B, Kinney W, Fetterman B, Poitras N, Lorey T, Schiffman M, Dunne A, Ostolaza J, McKinney S, Burk RB. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 2011; 20:946-953 [PMCID: 3117227]
  • Gage JC, Schiffman M, Wentzensen N, Akinfolarin AC, Eklund C, Reilly M, Hutchinson M, Harford J, Soliman A, Burk RD, Olusegun AK, The age-specificprevalence of human papillomavirus and cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. Int J Cancer 2011; In press
  • Katki HA, Wacholder S, Solomon D, Castle PE, Schiffman M. Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncology 2009; 10:1022-1023 [PMCID: 2789459]
  • Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12:663-672
  • Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Rodriguez AC, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Solomon D, Castle PE, Burk RD. A population-based case-control study of carcinogenic human papillomavirus (HPV) variants, viral persistence, and cervical neoplasia. Cancer Res 2010; 70:3159-3169 [PMCID: 2855741]
  • Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, Sahasrabuddhe V, Gravitt PE, Hsing AW, Burk RD. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PloS One 2011; 6:e20183 [PMCID: 3103539]
  • Mirabello L, Sun C, Ghosh A, Rodrihuez AC, Schiffman M, Wentzensen N, Hildesheim A, Herrero R, Wacholder S, Lorincz A, Burk RD. Hypermethylation of the HPV16 genome is associated with cervical intraepithelial neoplasia grade 3.
  • Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103:368-383 [PMCID: 3046952]
  • Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008; 26:451-464 [PMCID: 2574230]
  • Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, Hildesheim A, Rodriguez AC, Solomon D, Herrero R, Schiffman M; for the CVT group. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010; 340:c712 [PMCID: 2831171]
  • Campos NG, Kim J, Castle PE, Schiffman M. Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. Med Decision Making 2011; In revisions
  • Gage JC, Castle PE. Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst 2010; 102:1524-1527
  • Dunn BK, Greene MH, Kellyey JM, et al . Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet 2010; 1:332-349 [PMCID: 299292]